April 18, 2018 / 12:24 PM / 7 months ago

BRIEF-Fibrocell Announces Review Of Strategic Alternatives

April 18 (Reuters) - Fibrocell Science Inc:

* FIBROCELL ANNOUNCES REVIEW OF STRATEGIC ALTERNATIVES

* FIBROCELL SCIENCE INC - HAS ENGAGED CANACCORD GENUITY LLC AS ITS STRATEGIC FINANCIAL ADVISOR TO ASSIST WITH THIS REVIEW PROCESS

* FIBROCELL - POTENTIAL STRATEGIC ALTERNATIVES MAY INCLUDE SALE OF CO, BUSINESS COMBINATION, MERGER OR REVERSE MERGER WITH ANOTHER CO

* FIBROCELL - POTENTIAL STRATEGIC ALTERNATIVES MAY INCLUDE STRATEGIC INVESTMENT INTO CO, SALE, LICENSE OR OTHER DISPOSITION OF CORPORATE ASSETS

* FIBROCELL - POTENTIAL STRATEGIC ALTERNATIVES MAY INCLUDE CONTINUING WITH CURRENT BUSINESS PLAN

* FIBROCELL SCIENCE INC - IN STRATEGIC REVIEW, BOARD IS CONSIDERING FIBROCELL'S CLINICAL PROGRAMS FOR RARE SKIN DISEASES WITH UNMET NEEDS AMONG OTHERS

* FIBROCELL SCIENCE - INTENDS TO CONTINUE ADVANCING PHASE 1/2 CLINICAL TRIAL OF FCX-007 AND PROVIDE A TRIAL UPDATE IN Q2 OF 2018

* FIBROCELL - BELIEVES CASH AND CASH EQUIVALENTS AS OF MARCH 31 WILL BE SUFFICIENT TO FUND OPERATIONS INTO Q1 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below